Chinese Medical Journal,
Journal Year:
2022,
Volume and Issue:
135(10), P. 1163 - 1171
Published: May 20, 2022
Abstract
Non-alcoholic
fatty
liver
disease
(NAFLD)
is
one
of
the
fastest-growing
diseases,
and
its
global
prevalence
estimated
to
increase
>50%
by
2030.
NAFLD
comorbid
with
metabolic
syndrome,
obesity,
type
2
diabetes,
insulin
resistance.
Despite
extensive
research
efforts,
there
are
no
pharmacologic
or
biological
therapeutics
for
treatment
NAFLD.
Bile
acids
sphingolipids
well-characterized
signaling
molecules.
Over
last
few
decades,
researchers
have
uncovered
potential
mechanisms
which
bile
regulate
hepatic
lipid
metabolism.
Dysregulation
acid
sphingolipid
metabolism
has
been
linked
steatosis,
inflammation,
fibrosis
in
patients
This
clinical
observation
recapitulated
animal
models,
well-accepted
experts
hepatology
field.
Recent
transcriptomic
lipidomic
studies
also
show
that
important
players
pathogenesis
Moreover,
identification
as
activators
sphingolipid-mediated
pathways
established
a
novel
theory
biology.
In
this
review,
we
summarize
recent
advances
understanding
contributors
A
better
pathologic
effects
mediated
will
facilitate
development
new
diagnostic
therapeutic
strategies
Liver International,
Journal Year:
2021,
Volume and Issue:
41(4), P. 683 - 691
Published: Jan. 16, 2021
Fatty
liver
disease
associated
with
metabolic
dysfunction
is
the
most
prevalent
worldwide,
though
both
patient
and
health
professional
still
lack
awareness
of
it.
An
international
consensus
panel
has
produced
what
sure
to
be
an
influential
report
renaming
from
non-alcoholic
fatty
(NAFLD)
(dysfunction)
(MAFLD)
suggesting
how
should
diagnosed.
This
viewpoint
explores
call
perspective
nurse
allied
practitioners.
group
have
raised
serious
concerns
on
existing
nomenclature,
which
labels
as
NAFLD,
its
diagnostic
criteria,
including
provoking
role
confusion
representing
a
major
barrier
various
key
aspects;
patient-nurse
communications,
awareness,
partnership
working,
motivation
patients
undertake
lifestyle
changes
multiple
behaviour
change
promotion
nurse-led
clinics.
Therefore,
they
are
enthusiastically
supportive
this
reframe
that
we
believe
will
ultimately
positive
impact
nurse-patient
communication,
through
this,
improve
care
quality
life
reduce
burden
system.
Journal of Clinical and Translational Hepatology,
Journal Year:
2022,
Volume and Issue:
10(2), P. 230 - 237
Published: Jan. 4, 2022
Background
and
AimsWe
compared
lung
function
parameters
in
nonalcoholic
fatty
liver
disease
(NAFLD)
metabolic
dysfunction-associated
(MAFLD),
examined
the
association
between
fibrosis
severity
MAFLD.
Clinical and Molecular Hepatology,
Journal Year:
2022,
Volume and Issue:
28(4), P. 725 - 738
Published: March 14, 2022
Non-alcoholic
fatty
liver
disease
(NAFLD)
has
become
the
most
common
chronic
with
a
global
prevalence
of
about
55%
in
people
type
2
diabetes
mellitus
(T2DM).
T2DM,
obesity
and
NAFLD
are
three
closely
inter-related
pathological
conditions.
In
addition,
T2DM
is
one
strongest
clinical
risk
factors
for
faster
progression
to
non-alcoholic
steatohepatitis
(NASH),
cirrhosis
hepatocellular
carcinoma.
Increasing
evidence
suggests
that
newer
classes
glucose-lowering
drugs,
such
as
peroxisome
proliferator-activated
receptor
agonists,
glucagon-like
peptide-1
dipeptidyl
peptidase-4
inhibitors
or
sodium-glucose
cotransporter-2
inhibitors,
could
reduce
rates
progression.
This
narrative
review
aims
briefly
summarize
recent
results
from
randomized
controlled
trials
testing
efficacy
safety
old
new
drugs
treatment
NASH
adults
both
without
coexisting
T2DM.
Chinese Medical Journal,
Journal Year:
2022,
Volume and Issue:
135(10), P. 1163 - 1171
Published: May 20, 2022
Abstract
Non-alcoholic
fatty
liver
disease
(NAFLD)
is
one
of
the
fastest-growing
diseases,
and
its
global
prevalence
estimated
to
increase
>50%
by
2030.
NAFLD
comorbid
with
metabolic
syndrome,
obesity,
type
2
diabetes,
insulin
resistance.
Despite
extensive
research
efforts,
there
are
no
pharmacologic
or
biological
therapeutics
for
treatment
NAFLD.
Bile
acids
sphingolipids
well-characterized
signaling
molecules.
Over
last
few
decades,
researchers
have
uncovered
potential
mechanisms
which
bile
regulate
hepatic
lipid
metabolism.
Dysregulation
acid
sphingolipid
metabolism
has
been
linked
steatosis,
inflammation,
fibrosis
in
patients
This
clinical
observation
recapitulated
animal
models,
well-accepted
experts
hepatology
field.
Recent
transcriptomic
lipidomic
studies
also
show
that
important
players
pathogenesis
Moreover,
identification
as
activators
sphingolipid-mediated
pathways
established
a
novel
theory
biology.
In
this
review,
we
summarize
recent
advances
understanding
contributors
A
better
pathologic
effects
mediated
will
facilitate
development
new
diagnostic
therapeutic
strategies
